Orforglipron
Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.
Open Orforglipron in the 3D analyzerAnalytical specification
| Empirical formula | C45H52F3N7O7 |
|---|---|
| Molecular weight | 882.9 g/mol |
| Isoelectric point (pI) | 7.10 |
| Assay purity (HPLC) | 99.10% |
| Retention time | 4.80 min |
| Peak area / height | 9800 / 850 |
| Reference batch | OR-2026-P03 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Non-peptide small molecule mimicking peptide GLP-1 agonism targets |
Research characteristics
Oral Bioavailability
Resists enzymatic gastric degradation
Small Molecule
Allows clinical research comparison
Target Agonism
Full GLP-1 receptor pathway trigger
Clearance Profile
Extended half-life active presence
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.